We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

Stanford Medicine researchers have built CRISPR-GPT, a large language model designed to automate the full arc of gene-editing ...

The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells engineered inside the human body, a mouse study has found. Cancer-fighting ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $46.93, demonstrating a -1.59% change from the preceding day's closing price. This change lagged the S&P 500's 0.28% loss on the day.

CRISPR Therapeutics (NasdaqGM:CRSP) reports strong commercial momentum for its gene therapy CASGEVY, with patient initiations nearly tripling year over year. The company is preparing a regulatory ...

Earlier in March 2026, CRISPR Therapeutics completed a US$550 million private offering of 1.7308% Convertible Senior Unsecured Notes due March 1, 2031, issued under Rule 144A to bolster its funding ...

A vanadium MXene nanoparticle uses gene editing to strip tumors of heat resistance, then kills them with laser-triggered free ...

After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a ...

CRISPR Therapeutics (NASDAQ:CRSP) has had a rough stretch lately. Shares have dropped 5% over the past week and are down 8% year-to-date, trading around $49.37 as of Tuesday morning. Piper Sandler, ...

Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...

Neither the Parties nor the Patent Trial and Appeal Board (PTAB) have been resting in addressing the decision by the Federal Circuit that vacated ...